



Description générale

A fixed-dose combination regimen of the direct acting antiviral agents sofosbuvir and velpatasvir for the treatment of genotypes 1-6 chronic hepatitis C virus (HCV) infection.

| | |
|----------------------------|--|
| INN | Sofosbuvir + velpatasvir |
| Codes ATC | J05AP55 |
| Type de médicament | Chemical agent |
| Historique des statuts LME | Ajouté pour la première fois en 2017 (TRS 1006) pour Chronic hepatitis C |
| Wikipédia | Sofosbuvir + velpatasvir ↗ |
| DrugBank | Sofosbuvir ↗ Velpatasvir ↗ |

Recommandations

Section Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg

Indications

Chronic hepatitis C

